WO2023059362A1 - Système combiné de médicament et de diagnostic pour identifier et traiter des virus à arn simple brin notamment des coronavirus - Google Patents

Système combiné de médicament et de diagnostic pour identifier et traiter des virus à arn simple brin notamment des coronavirus Download PDF

Info

Publication number
WO2023059362A1
WO2023059362A1 PCT/US2022/011251 US2022011251W WO2023059362A1 WO 2023059362 A1 WO2023059362 A1 WO 2023059362A1 US 2022011251 W US2022011251 W US 2022011251W WO 2023059362 A1 WO2023059362 A1 WO 2023059362A1
Authority
WO
WIPO (PCT)
Prior art keywords
favipiravir
ivermectin
administered
agent
subject
Prior art date
Application number
PCT/US2022/011251
Other languages
English (en)
Inventor
Carl Johan Freer
Richard Kaszynski
Alessandro Gadotti
Original Assignee
AiPharma Global Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/565,675 external-priority patent/US11439638B1/en
Application filed by AiPharma Global Holdings LLC filed Critical AiPharma Global Holdings LLC
Publication of WO2023059362A1 publication Critical patent/WO2023059362A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention concerne une méthode de traitement d'une infection microbienne à un stade précoce consistant à déterminer si un sujet est exposé à un coronavirus, tel que le SARS-CoV-2, ou suspecté d'être exposé à un microbe, ou exposé à un autre sujet infecté ou suspecté d'être infecté par un coronavirus et, si le sujet est infecté par le coronavirus, à administrer un agent antimicrobien.
PCT/US2022/011251 2021-10-06 2022-01-05 Système combiné de médicament et de diagnostic pour identifier et traiter des virus à arn simple brin notamment des coronavirus WO2023059362A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163253084P 2021-10-06 2021-10-06
US63/253,084 2021-10-06
US17/565,675 US11439638B1 (en) 2021-10-06 2021-12-30 Drug and diagnostic combination system to identify and treat single-stranded RNA viruses including coronaviruses
US17/565,675 2021-12-30

Publications (1)

Publication Number Publication Date
WO2023059362A1 true WO2023059362A1 (fr) 2023-04-13

Family

ID=80123262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/011251 WO2023059362A1 (fr) 2021-10-06 2022-01-05 Système combiné de médicament et de diagnostic pour identifier et traiter des virus à arn simple brin notamment des coronavirus

Country Status (1)

Country Link
WO (1) WO2023059362A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399261B2 (en) 2007-06-27 2013-03-19 Inbios International, Inc. Lateral flow assay system and methods for its use
EP3854398A1 (fr) * 2020-01-21 2021-07-28 Academy of Military Medical Sciences Utilisation de favipiravir dans le traitement d'une infection à coronavirus
WO2021262825A2 (fr) * 2020-06-23 2021-12-30 Genetic Networks, Llc Perturbation de synthèse de lipides : une nouvelle cible pour agents thérapeutiques anti-virulence à large spectre dirigés vers l'hôte

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399261B2 (en) 2007-06-27 2013-03-19 Inbios International, Inc. Lateral flow assay system and methods for its use
EP3854398A1 (fr) * 2020-01-21 2021-07-28 Academy of Military Medical Sciences Utilisation de favipiravir dans le traitement d'une infection à coronavirus
WO2021262825A2 (fr) * 2020-06-23 2021-12-30 Genetic Networks, Llc Perturbation de synthèse de lipides : une nouvelle cible pour agents thérapeutiques anti-virulence à large spectre dirigés vers l'hôte

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AGRAWAL UMANG ET AL: "Favipiravir: A new and emerging antiviral option in COVID-19", vol. 76, no. 4, 2 September 2020 (2020-09-02), IN, pages 370 - 376, XP055788367, ISSN: 0377-1237, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467067/pdf/main.pdf> DOI: 10.1016/j.mjafi.2020.08.004 *
ANON: "A Double-blind Randomized Controlled Trial of Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients NCT05155527", 13 December 2021 (2021-12-13), XP055927202, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/study/NCT05155527> [retrieved on 20220601] *
ANON: "Summary of opinion (initial authorisation) Veklury Remdesivir", 25 June 2020 (2020-06-25), XP055926934, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/medicines/human/EPAR/veklury#:~:text=Veklury%20received%20a%20conditional%20marketing,EU%20on%203%20July%202020.> [retrieved on 20220601] *
CARTER LINDA J. ET AL: "Assay Techniques and Test Development for COVID-19 Diagnosis", ACS CENTRAL SCIENCE, vol. 6, no. 5, 27 May 2020 (2020-05-27), pages 591 - 605, XP055822886, ISSN: 2374-7943, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197457/pdf/oc0c00501.pdf> DOI: 10.1021/acscentsci.0c00501 *
FURUTA ET AL., PROC JPN ACAD SER B PHYS BIOL SCI, 2017
HASSANIPOUR ET AL., SCI REP.,, 2021
JITOBAOM ET AL., RESEARCH SQUARE, 2021
SIDDIQUI ARIF JAMAL ET AL: "Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2", JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, vol. 39, no. 17, 5 August 2020 (2020-08-05), US, pages 6828 - 6841, XP055920474, ISSN: 0739-1102, DOI: 10.1080/07391102.2020.1802345 *

Similar Documents

Publication Publication Date Title
Perna et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance
JP2017525681A (ja) パラミクソウイルスの治療方法
AU2006322120B2 (en) Benzimidazole non-aqueous compositions
US11439638B1 (en) Drug and diagnostic combination system to identify and treat single-stranded RNA viruses including coronaviruses
HU215443B (hu) Többféle hatóanyagot tartalmazó gyógyszerkészítmények, főként hüvelykúp, baktericid, fungicid, protozoa- és vírusellenes kombinált hatással
EP3944736A1 (fr) Avermectines destinées à être utilisées dans le traitement d&#39;une infection par coronaviridae
Reyns et al. Disposition and oral bioavailability of amoxicillin and clavulanic acid in pigs
US11446320B1 (en) Pharmaceutical combination having potent antiviral activity against single-stranded RNA viruses
WO2021198511A1 (fr) Méthodes et compositions pour le traitement d&#39;une infection par sars-cov-2
WO2023059362A1 (fr) Système combiné de médicament et de diagnostic pour identifier et traiter des virus à arn simple brin notamment des coronavirus
WO2023059363A1 (fr) Combinaison pharmaceutique ayant une activité antivirale puissante contre des virus à arn simple brin
Six et al. Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients
US20240100025A1 (en) Materials and Methods for Treating Viral and Other Medical Conditions
AU2016396042A1 (en) Compositions and methods for treatment of influenza virus
US20230213515A1 (en) Drug and diagnostic combination system to identify and treat single-stranded rna viruses including coronaviruses and monkeypox
CA2443068A1 (fr) Compositions veterinaires comprenant des derives d&#39;oxime avermectine et du praziquantel
US20230210844A1 (en) Pharmaceutical combination having potent antiviral activity against single-stranded rna viruses including coronaviruses and monkeypox
CN114762694B (zh) 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
US20040151744A1 (en) Avermectin and praziquantel combination therapy
KR20220150348A (ko) 코로나바이러스의 치료에 조합하여 사용하기 위한 pld
JP7293225B2 (ja) 組合せ製品を用いるｒｓｖの処置
Osawa et al. Maculopapular rash induced by oral vancomycin
KR100227125B1 (ko) 미포자충감염을치료하기위한벤즈이미다졸구충제의용도
ZA200604043B (en) Multiple active agents such as anthelmintics sustained release delivery
US20230123135A1 (en) Method of treatment using meta-arsenite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22701754

Country of ref document: EP

Kind code of ref document: A1